STUDIES ON FACTORS AFFECTING BUSINESS PERFORMANCE
OF BIOTECHNOLOGY COMPANIES

HESHAM ALI EL ENSHASY

A Dissertation submitted in partial fulfillment of the
requirements for the award of the degree of
Master of Management (Technology)

Faculty of Management and Human Resource Development
UNIVERSITI TEKNOLOGI MALAYSIA

FEBRUARY 2012
To the memory of my parents
To my uncle Hassan
To my wife Rania and my big boy Ali
To my sisters Hend and Hoda
ACKNOWLEDGEMENTS

In preparing this thesis, I was in contact with many people, academicians, industrial experts and colleagues who supported me to understand the multidimensional characteristics of this research. With my deep sense of gratitude, I wish to express my sincere thanks to my supervisor Prof. Dr. Amran Rasli for his continuous support, expert supervision, stimulating suggestions and immense help in planning and executing this research. I would like also to express my sincere thanks to Dr. Amit Jushi for his generosity and support of this work. My research would not be possible to conduct without the magnificent contributions of the EOA expert panel of this study. It was great experience working with you. My sincere thanks for you all sharing your knowledge and experience and for being patience and commitment during the different phases of this research.

I am also very thankful to all my teachers in the Faculty of Human Resource and Management (Universiti Teknologi Malaysia) who helped me a lot to understand the multi dimensional characteristics of business research. My sincere appreciation also extends to Ms. Lim and Ms. Rosnah who have provided assistance at various occasions. I wish I would never forget the company I had with my colleagues during my study at UTM. I would like also to thank my business partners and friends Mr. Salah abdel Fattah, Dato Tony Peng, Mr. Ramaness, Mr. Adam Durmick, Mr. Evangelos Bonoris, Ms. Maria Tsamboula who shared with me their business experience for many years.

I also want to thank my dear brothers Prof. Ramlan Aziz and Prof. Roji Sarmidi for their support in this study. Last, but not least, I would like to thank my lovely partner Rania for her endless support throughout my M.Sc. study. Without her love and understanding for not having family weekends for two years, I simply could not have completed this thesis.
ABSTRACT

Biotechnology industries are fast growing, technology based and multibillion dollars business. Biotechnology dealt with using biomaterials to produce bioproducts or to provide service in many industrial sectors of health, food, chemical and environmental industries. Like most of high-tech business, biotechnology is long term investment business with high risk. Therefore, based on the unique nature of this business, factors affecting its performance are different from those of ordinary business. Thus, this study is focused on the determination of the current factors affecting the performance of biotechnology business by 46 worldwide experts using mixed research method (a combination between Expert Opinion Assessment EOA technique and questionnaire of closed ended questions). Two rounds of questioning were conducted to identify, categorize and prioritize these factors by mean ranks. In the first round, experts listed all factors affecting business performance. The results of the first round were grouped and returned to the experts in the second round to score the importance of each factor. The second round showed high results consensus among the experts. Based on the favorable Kendall’s coefficient of consensus, it was not necessary to run the third round. Based on the results obtained from EOA study, a non-Financial Business Performance Indicator (n-FBPI) was developed for quantitative determination of performance of biotechnology companies. To evaluate the company’s performance, another research instrument (questionnaire) was developed. This questionnaire composed of 97 questions to evaluate the company’s external and internal environment and strength in points related to the effective factors uncovered in the first part of this study. The developed instrument was tested by 5 companies and gave quantitative measure for companies performance. Furthermore, a new website (www.biotechhorizon.com) was developed for this study for online assessment of the performance of biotechnology companies. The results of this study will help all stakeholders in biotechnology business either who are new in this type of business or who are well established by providing the current factors which have significant effect on biotechnology business performance. The n-FBPI developed will also be a useful tool for companies to evaluate their non financial performance quantitatively.
ABSTRAK

TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>CHAPTER</th>
<th>TITLE</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>TITLE PAGE</td>
<td></td>
<td>i</td>
</tr>
<tr>
<td>DECLARATION</td>
<td></td>
<td>ii</td>
</tr>
<tr>
<td>DEDICATION</td>
<td></td>
<td>iv</td>
</tr>
<tr>
<td>ACKNOWLEDGEMENTS</td>
<td></td>
<td>v</td>
</tr>
<tr>
<td>ABSTRACT</td>
<td></td>
<td>vi</td>
</tr>
<tr>
<td>ABSTRAKT</td>
<td></td>
<td>vii</td>
</tr>
<tr>
<td>TABLE OF CONTENT</td>
<td></td>
<td>viii</td>
</tr>
<tr>
<td>LIST OF TABLES</td>
<td></td>
<td>xiii</td>
</tr>
<tr>
<td>LIST OF FIGURES</td>
<td></td>
<td>xv</td>
</tr>
<tr>
<td>LIST OF APPENDICES</td>
<td></td>
<td>xvii</td>
</tr>
<tr>
<td>LIST OF ABBREVIATIONS</td>
<td></td>
<td>xviii</td>
</tr>
</tbody>
</table>

1 INTRODUCTION 1
1.1 Research background 1
1.2 Statement of the problem 3
1.3 Purpose of the study 4
1.4 Objectives of the study 5
1.5 Research questions 5
1.6 Operational definition 6
1.6.1 Biotechnology 6
1.6.2 Business performance 7
1.6.2 Delphi method (EOA method) 8
1.7  Scope of the study  9
1.8  Importance and significance of the study  9
1.9  Limitation of the study  10
1.10 Plan of the thesis  10

2  LITERATURE REVIEW  12
2.1  Business performance and measures  12
2.2  Business performance measurement of network  15
2.3  Biotechnology business  16
2.4  Factors affecting business performance  17
   in biotechnology sector
   2.4.1  Fund availability  20
   2.4.2  Innovation capability  22
   2.4.3  Marketing ability  24
   2.4.4  Technology availability  26
   2.4.5  Public acceptance  26
   2.4.6  Political factors  28
   2.4.7  Networking  30
   2.4.8  Regulatory issues  32
   2.4.9  Human capital capacity  33
   2.4.10 Business location and related issues  34
2.5  Relations between factors affecting business performance  35
2.6  Research framework  35
2.7  Summary  37

3  METHODOLOGY  38
3.1  Research design  39
3.2  Research tool for data collection  41
   (Mixed Methods Research)
   3.2.1  Delphi/Expert Opinion Assessment (EOA)  42
      method of research
3.2.1.1 Criticism for Delphi method 44
3.2.1.2 Methods to overcome the disadvantages/ limitations of EOA Method 46

3.3 Development of EOA instrument 48
3.3.1 Identification and selection of the expert panel 48
3.3.2 Preparation of question 50
3.3.3 Running EOA method 51
3.3.4 Hypothesis testing and analysis using Kendall’s Coefficient of concordance 55

3.4 Development of general and specific non-Financial Business Performance Indicator (n-FBPI) for Biotech. companies 56

3.5 Data collection process 57
3.6 Summary 58

4 FINDINGS 60
4.1 Introduction 60
4.2 Determination of factors affecting business performance of biotech. companies (first round of EOA)
4.2.1 RQ1. What factors are deemed As important for business performance of biotech. companies 62
4.2.1.1 Profile of respondents in EOA research (first round of EOA) 63
4.2.1.2 Feedback and responses from the first round of EOA 64

4.3 Determination of weight of factors affecting business performance of biotech. companies (second round of EOA)
4.3.1 RQ2: How are the aforementioned factors ranked? 79
4.3.2 Profile of respondent in EOA research (second round) 80

4.4 Summary 81
4.3.3  Determination of weight of factors affecting the business performance 83
4.3.4  Determination of weight of individual factor based on geographic and demographic information of the Experts 105
4.4  Determination of weight of factors affecting business performance of biotech. companies (second round of EOA) 115
   4.4.1 RQ3: How the non-financial performance of Biotech companies could be determined quantitatively? 115
   4.4.2  Development of different n-FBP Indexes 116
      4.4.2.1. Non-specific n-FBP Index (1 Index) 116
      4.4.2.2. specific n-FBP Index (6 Indexes) 117
   4.4.3. Empirical quantitative determination of n-FBP of biotech. companies 118
4.5  Design of dedicated web-based research instrument for online measurement of n-FBP of biotech. companies 131
   4.5.1 RQ4: How best can a dedicated instrument be developed to measure non-financial performance of biotechnology companies taking in consideration the factors uncovered in this study? 131

5  DISCUSSION, CONCLUSIONS, AND RECOMMENDATIONS 135
5.1  Introduction 135
5.2  Discussion of the findings 136
   5.2.1 Profile of the experts involved in this study 136
   5.2.2 Factors affecting n-FBP in biotech. business 137
   5.2.3 Evaluation of the importance of individual facto in biotech. business performance 139
   5.2.4 Quantitative determination of n-FBP of biotech. companies 142
5.3  Conclusions  
5.4  Recommendations for further research  

REFERENCES  

APPENDIXES  

Appendix A  
Appendix B  
Appendix C  
Appendix D
## LIST OF TABLES

<table>
<thead>
<tr>
<th>TABLE NO.</th>
<th>TITLE</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1</td>
<td>Feedback of the biotechnology business expert panel for EOA study (first round).</td>
<td>65</td>
</tr>
<tr>
<td>4.2</td>
<td>Complete factors affecting the business performance of biotechnology business according to the first round of EOA</td>
<td>77</td>
</tr>
<tr>
<td>4.3</td>
<td>Experts involved in the second round of EOA</td>
<td>81</td>
</tr>
<tr>
<td>4.4</td>
<td>Second round survey results of EOA</td>
<td>89</td>
</tr>
<tr>
<td>4.5</td>
<td>Expert opinion of the second round of EOA sorted by weight of factors (All experts) n=40</td>
<td>102</td>
</tr>
<tr>
<td>4.6</td>
<td>Experts opinion of the second round of EOA ranked by factor’s weight (Regional vs. International)</td>
<td>112</td>
</tr>
<tr>
<td>4.7</td>
<td>Experts opinion of the second round of EOA ranked by factor’s weight (Non-medical vs. Medical)</td>
<td>113</td>
</tr>
<tr>
<td>4.8</td>
<td>Basic data of biotechnology companies evaluated using n-FBP Index</td>
<td>119</td>
</tr>
<tr>
<td>4.9</td>
<td>Determination of n-FBP index of company A based on non-specific ranking system.</td>
<td>121</td>
</tr>
<tr>
<td>Section</td>
<td>Description</td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>-------------</td>
<td></td>
</tr>
<tr>
<td>4.10</td>
<td>Determination of n-FBP index of company B based on non-specific ranking system.</td>
<td></td>
</tr>
<tr>
<td>4.11</td>
<td>Determination of n-FBP index of company C based on non-specific ranking system.</td>
<td></td>
</tr>
<tr>
<td>4.12</td>
<td>Determination of n-FBP index of company D based on non-specific ranking system.</td>
<td></td>
</tr>
<tr>
<td>4.13</td>
<td>Determination of n-FBP index of company E based on non-specific ranking system.</td>
<td></td>
</tr>
<tr>
<td>4.14</td>
<td>The values of specific and non-specific n-FBP of the biotech companies involved in this study.</td>
<td></td>
</tr>
<tr>
<td>5.1</td>
<td>The top ten factors affecting business performance based on Expert’s geographic and demographic background</td>
<td></td>
</tr>
</tbody>
</table>
### LIST OF FIGURES

<table>
<thead>
<tr>
<th>FIGURE NO.</th>
<th>TITLE</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1</td>
<td>Dimensions of ENBSC</td>
<td>15</td>
</tr>
<tr>
<td>2.2</td>
<td>Axis of product-based (sectors) in biotechnology:</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>A combination of ‘core biotechnology’ and sectors</td>
<td></td>
</tr>
<tr>
<td>2.3</td>
<td>Networks of key factors influencing innovation</td>
<td>24</td>
</tr>
<tr>
<td>2.4</td>
<td>Proposed Research Framework of the study</td>
<td>36</td>
</tr>
<tr>
<td>3.1</td>
<td>Flowchart for the research method</td>
<td>40</td>
</tr>
<tr>
<td>4.1</td>
<td>Geographic, demographic and field of expertise for experts who involved in the first round of EOA.</td>
<td>64</td>
</tr>
<tr>
<td>4.2</td>
<td>Geographic, demographic and field of expertise for experts who involved in the second round of EOA.</td>
<td>82</td>
</tr>
<tr>
<td>4.3</td>
<td>The weight of factors affecting the n-FBP according to all experts opinion (n=40)</td>
<td>101</td>
</tr>
<tr>
<td>4.4</td>
<td>The weight of factors affecting the n-FBP according to regional experts opinions (n=18)</td>
<td>108</td>
</tr>
</tbody>
</table>
4.5 The weight of factors affecting the n-FBP according to international experts opinions (n=22) 108
4.6 The weight of factors affecting the n-FBP according to non-medical biotech. experts opinions (n=18)’ 109
4.7 The weight of factors affecting the n-FBP according to medical experts opinions. (n=22) 109
4.8 The weight of factors affecting the n-FBP according to the opinions of experts from universities, government and consultants (n=19). 110
4.9. The weight of factors affecting the n-FBP according to the responses of experts from industries (n=21). 110
4.10 Flowchart for determination of n-FBP for biotech. companies using non-specific n-FBP Index. 133
4.11 Flowchart for determination of n-FBP of biotech. companies using specific n-FBP Indexes. 134
# LIST OF APPENDICES

<table>
<thead>
<tr>
<th>APPENDIX</th>
<th>TITLE</th>
<th>PAGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Expert opinion assessment documentation</td>
<td>144</td>
</tr>
<tr>
<td>B</td>
<td>Questionnaire for evaluation of non Financial Business Performance Indicator (n-FBPI) for Biotechnology Business</td>
<td>158</td>
</tr>
<tr>
<td>C</td>
<td>The differences in factors weights based on geography, demography and type of industry of expert involved in the second round of EOA</td>
<td>174</td>
</tr>
<tr>
<td>D</td>
<td>n-FBP Indexes developed in this study</td>
<td>214</td>
</tr>
</tbody>
</table>
LIST OF ABBREVIATIONS

BINGOs  Business Interest non-Governmental Organizations
BPM     Business Performance Management
CEO     Chief Executive Officer
COO     Chief Operating Officer
CRO     Contract Research Organization
EOA     Expert Opinion Assessment
FDA     Food and Drug Administration
GLP     Good Laboratory Practice
GM      Genetically Modified
GMO     Genetically Modified Organism
cGMP    current Good Manufacturing Practice
IPR     Intellectual Property Rights
KAVDM   Knowledge Assets Value Dynamic Map
MENA    Middle East and North Africa
n-FBP    non-Financial Business Performance
n-FBPI   non-Financial Business Performance Indicator
NTBFs   New Technology Based Firms
OECD    Organization for Economic Co-operation and Development
PINGOs  Public Interest non-Governmental Organizations
PMS     Performance Measurement Systems
POH     Pecking Order Hypothesis
R&D     Research and Development
RTD     Research and Technology Development
TT      Technology Transfer
VC:     Venture Capital
CHAPTER 1

INTRODUCTION

1.1 Research background

Biotechnology is one of the high-tech and knowledge based industry and considered as the most dynamic and diverse business sector in the 21st century. Biotechnology based products are usually innovative and come as a result of long time intensive research. The products of biotechnology industries are covering a wide range of our daily used products from agriculture biofertilizers to recombinant insulin and vaccine. Thus, studying the factors affecting the performance of biotechnology business is an interesting topic for research.

The success of any organization is usually affected by many factors which govern the success and sustainability of business. Thus, business performance measurement is a critical process to ensure the healthy and sustainable growth of any organization. Therefore, determination of the proper method of business performance measurement is a matter of interest for many researchers (Neely, 2007; Taticchi, 2010). Measures of business performance can be used as indicators and factors affecting these measures can be considered as drivers and key factors for organization success. These factors are usually linked directly to nature and
activities of the organization. However, factors affecting business performance are not standard and dependent on business sector. Moreover, those factors are dynamic and the weight of each factor is changeable based on external business environment.

Based on the uniqueness feature of biotechnology business, success measures and factors affecting business performance in biotechnology industry may differ from those of other types of business. For example, innovation is usually the main success factor in biotech industry and used as large measure and indicator for firm’s success and sustainability (Chen, 2004). Innovativeness is heavily dependent on the company’s long term Research and Technology Development (RTD) efforts. In other sectors like the car industries, business performance is highly affected by marketing, technology availability and supply chain effect. Moreover, biotechnology is also subject to more security issues and debate than other new technologies. This based on the fact that genetically modified organisms, especially those used in the food supply chain, many have a negative effect on human health and the risk of genetically modified crops may persist in the soil and affect the environment in general (Traore and Rose, 2003). Therefore, customer acceptance and regulatory effect on business performance are critical factors in case of the biotechnology industry. Moreover, biotechnology industry include also ethical concern when they use issues of high debates and uncertain acceptance regarding to moral and religious perspective such as using embryonic stem cells and cloning.

The present work will focus on the determination of the critical factors which can affect the business performance of Biotechnology companies. This research will provide suggestions for biotechnology companies to increase their business performance.
1.2 Statement of the problem

Biotechnology business is multibillions high-tech and innovation based. Biotechnology is huge multi-billion dollar industries. This business sector generated total revenues of $171.8 billion in 2007, representing a compound annual growth rate (CAGR) of 10.7% for the period spanning 2003-2007 (Tan, 2009). However, market share of each sector are not equally. According to the biotechnology market report done by Tan (2009), the medical/healthcare segment is the most important sector and share about 69.4% of the market’s overall value followed by service provider segment which contribute to 14.7% of the market’s aggregate revenues. Agriculture/environmental biotechnology sector comes in the third stage followed by industrial biotechnology (non-medical) industries.

However, this type of industry is relatively new compared to other known and well established business like steel, car manufacturing and electronic industries. Based on previously published reports, factors affecting this type of business are highly diversified.

Many research papers investigated the effect of particular factor on biotechnology business growth and performance such as innovation ability (Hall and Bagchi-Sen, 2002; Hult et al., 2004), networking and cooperation (Audretsch, 2001; Festel et al., 2010) fund availability (Lee and Dibner, 2005; Chen and Marchioni (2008), and business location (van Geenhuizen and Reyes-Gonzales, 2007). Few others studied the effects of the co relatedness of two or more factors and investigated this combined relation on biotechnology business. For example, the combined effect of location and knowledge collaboration showed positive effect on the performance of Swedish biotechnology companies working in pharmaceutical sector (McKelvey et al., 2003). However, few researchers studied those factors as a group and discussed their integrated effects on the overall biotechnology firm’s performance. These studies were limited to particular country such as Canada
(Woiceshyn and Hartel, 1996). Another study conducted by Hsu et al., (2005) was focused on the effects of those factors related to governmental policies on new biotechnology firm’s performance in Taiwan. To the researcher’s knowledge, no research was conducted before using Delphi/EOA method to determine and rank the factors affecting business performance of biotechnology companies in global market. Moreover, as biotechnology is highly dynamic and fast growing industries, those factors affecting this business as well as their ranking can change very rapidly. Thus, the results published a couple of years ago may be less valid since many new factors may be raised and others may not exist anymore. Moreover, the level of importance of those factors is changeable very fast.

In the researcher’s opinion, determination of these factors with proper ranking of their influence on business performance is a research topic of high demand for all stakeholders of biotechnology businesses. As such, this research is timely as biotechnology is now revered as a powerful engine for industrial and technological growth of a nation.

1.3 Purpose of the study

The purpose of this study is to determine the factors that currently affecting the business performance of biotechnology companies based on expert opinion assessment method. In addition, the study aims to identify the weight of each factor and its degree of influence on biotechnology business. It is hoped that the outcomes of this research will provide better awareness about the real and current practical factors which are affecting biotechnology business performance. This study will also serve as guidelines for new biotechnology investors to have proper start up for their business and help also those companies who already in the market to perform better and enjoy healthy sustainable business growth. The outcomes of this research will also help as guidance for governmental bodies to understand what are required to
improve in term of business and investment environment to attract biotechnology companies and to support them for sustainable growth.

1.4 Objectives of the study

The objectives of the current research are as follows:

1- To identify the factors affecting the business performance of biotechnology companies based on expert opinion.
2- To evaluate the importance of each factor and how it affect the business performance.
3- To develop non-financial business performance indicator for biotechnology companies.
4- To design a dedicated web-based research instrument for online measurement of non financial business performance of biotechnology companies

1.5 Research Questions

This study addresses the following research questions:

1. What factors are deemed as important for business performance of biotechnology companies?
2. How are the aforementioned factors ranked?
3. How could the non-financial performance of biotechnology companies be determined quantitatively?
4. How best can a dedicated instrument be developed to measure non-financial performance of biotechnology companies taking in consideration the factors uncovered in this study?

1.6 Operational definitions

Key terminologies which will be used consistently throughout this study are defined as follows:

1.6.1 Biotechnology

Many definitions for the word biotechnology exist in literature to describe this modern science. It was defined as the field of applied biology that involves the use of living organisms and bioprocess in engineering, technology, medicine and other fields requiring bioproducts (Biotechnology: Wikipedia, 2011). However, the most acceptable definition for biotechnology is “the application of science and technology to living organisms, as well as parts, products and models thereof, to alter living or non-living materials for the production of knowledge, goods and services” (OECD, 2006:7).
1.6.2 Business performance

Performance shows a diversity of meaning. The usable definition in business was presented in the study of Lebas and Euske (2007) by the following three definitions:

1. To accomplish something with a specific intention (e.g. create value)
2. The result of action (the value created, however measured)
3. The ability to accomplish or the potential for creating a result (e.g. customer satisfaction, seen as measure of the potential of the organization for future sale).

According to Choe et al. (1997), business performance is evaluated as combined measure of the three major aspects of business performance: profitability, growth and manufacturing performance. In many research, Return of Assets (ROA) and growth are the most common indicators of business performance. Manufacturing performance is directly related to the four competitive priorities in manufacturing: cost efficiency, product quality, manufacturing flexibility, and dependability. According to the recent research of Tseng et al. (2009), five dimensions of business performance were identified. These are: competition performance, financial performance, manufacturing capability, innovation capability and supply chain relationship.
1.6.3 Delphi method (EOA method)

This technique was named after the ancient Greek oracle at Delphi from which prophecy was given (Koontz and O'Donnel, 1976). This research method was first developed by Dalkey and Helmer in the early 1950s to perform forecasting study for RAND Corporation to improve the technology of Douglas aircraft. The Delphi method was conceived as a group technique whose aim was to obtain the most reliable consensus of opinion of a group of experts by means of a series of intensive questionnaires with controlled opinion feedback (Dalkey and Helmer, 1963). This technique was also identified by Skutsch and Hall (1973) as follows: A method for gaining judgments on complex matters where precise information is unavailable. However, one of the basic definition in literature was provided by Linestone and Turoff, 1975) as follows: “Delphi is a method for structuring a group communication process so that the process is effective in allowing a group of individuals, as a whole, to deal with a complex problem”. Based on the initial forecasting application of this technique it was also defined as “a medium-term qualitative forecasting method that is based on building a consensus amongst a group of experts (Bonnemaizon et al., 2007).

Delphi was initially developed as a qualitative, long-range forecasting technique that elicits, refines, and draws upon the collective opinion and expertise of a panel of experts (van Zolinge and Klaassen, 2003). However, Delphi technique is not only limited to forecasting research but also was successfully used in many other studies such as strategy formulation through analyzing current problems related to setting objectives, generating alternatives, and evaluating potential strategies (Wedley, 1977; White et al., 2007). Therefore, this technique was recently defined as “Delphi is a group process involving an interaction between the researcher and a group of identified experts on a specified topic, usually through a series of questionnaires” (Yousuf 2007). Based on this definition, Delphi could be considered as wide scope technique for Expert Opinion Assessment (EOA) method for both current problem assessment and forecasting applications.
1.7 **Scope of the study**

This study is focused on only one type of industry: biotechnology industry. This will involve all stakeholders related directly or indirectly of this business. This includes experts who have knowledge, strong background and market information about this type of business. Delphi (Expert Opinion Assessment) method will be applied in this research in three rounds as the main research tool in this research. The results will be measured by number and presented through statistical analysis. The results obtained were used to develop a non Financial Business Performance (n-FBP) Index for quantitative measure of company’s performance in biotechnology sector using a simple research instrument (questionnaire).

1.8 **Importance and significance of the study**

Determination of factors affecting the business performance of biotechnology companies became important issues to understand the unique feature of this type of business. Therefore, this study will be of significant values for all stakeholders involved in biotechnology business such as (researchers, investors, companies, regulatory bodies and governmental agencies). However, the importance of this study could be summarized in the following points:

1. This study will give full determination of the main factors affecting business performance in biotechnology field based on the current expert’s opinion.
2. This research will identify the divergence and convergence in the opinion of expert about those factors
3. This research will help in the determination of the weight of each factor to understand the main driving factors in this type of business.

Thus, this study will give clear view of the factors which are critical for sustainable business performance in this type of industry.

1.9 Limitation of the study

There are some limitations that need to be acknowledged and addressed for the present study. This study will be conducted with help of a panel of experts in form of 40 persons who have deep knowledge of biotechnology industries. The first limitation is the availability of experts in this field who would like to share his/her knowledge in this type of business. Second, finding experts who have enough time and willing to spend time in these 3 rounds based research. Third, the time frame of this study is limited. Fourth, this study is limited in scope and the results obtained are highly specific to biotechnology industries and cannot be generalized to other business sector. Moreover, this research is mainly based on expert opinion; therefore the accuracy and reliability of our finding will be dependent on the degree of sincerity and truthfulness of the experts.

1.10 Plan of the thesis

The introduction chapter of this thesis represents an overview about the biotechnology business sector, statement of the problem, purpose and objective of this study, research questions, operational definition, scope of this study,
significance and limitation of the study. This outcomes of this research will help biotechnology based firms to understand the culture of this business through understanding the factors affecting the non-financial business performance of biotechnology companies. Furthermore, this will help also government policy makers to put new strategy to attract and to promote biotechnology based firms as key drivers in knowledge based economy. Furthermore, as this study ended by the development of non-Financial Business Performance Indicator (n-FBPI) Index, it will help biotech. companies to do proper assessment for their non-financial performance and to understand their strengths and weaknesses based on experts opinion.
CHAPTER 2

LITERATURE REVIEW

This section of thesis started by giving information about methods applied for measurement of business performance. Knowing these measures in the first step is important to understand the factors affecting business performance of this business. Following this, factors affecting business performance in biotechnology companies were determined based on previously published scientific papers, industrial organizations and governmental agencies. These factors were classified under 10 categories. However, most of these factors are interrelated and it is generally difficult to evaluate some of these factors independently.

2.1 Business performance and measures

Measuring performance is important to evaluate the success, progress and competitiveness for all types of organization. Performance measurement system (PMS) has different definitions in literatures. In our opinion, the most proper definition was set by Neely et al. (1995:81) as “the set of metrics used to quantify both the efficiency and effectiveness of actions.”
REFERENCES


http://www.ethicaltools.info/content/ET3%20Manual%20ED%20%28Binnenwerk%2043p%29.pdf


